Not yet a member?Join now!|Lost password
Novo Nordisk A/S
Novo Nordisk A/S
12/19/2012 | Press release
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 December 2012)
distributed by noodls on 12/19/2012 11:29
|
Read the full announcement in PDF format |
Bagsværd, Denmark, 19 December 2012 - Novo Nordisk today announced the completion of the phase 3a programme for IDegLira, a fixed-ratio combination of insulin degludec (Tresiba®), a once-daily new-generation basal insulin analogue, with an ultra-long duration of action, and liraglutide (Victoza®), the once-daily human GLP-1 analogue, as well as the decision to initiate phase 3 development for FIAsp, a faster-acting formulation of insulin aspart (NovoRapid®).
| Media: | ||
| Mike Rulis | +45 4442 3573 | mike@novonordisk.com |
| Ambre Morley (US) | +1 609 216 5240 | abmo@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 4442 4303 | krop@novonordisk.com |
| Frank Daniel Mersebach | +45 4442 0604 | fdni@novonordisk.com |
| Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
| Jannick Lindegaard (US) | +1 609 786 4575 | jlis@novonordisk.com |
Company announcement No 83 / 2012
